These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2162887)

  • 1. Identification of effector cell protease receptor-1. A leukocyte-distributed receptor for the serine protease factor Xa.
    Altieri DC; Edgington TS
    J Immunol; 1990 Jul; 145(1):246-53. PubMed ID: 2162887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease-dependent T cell activation: ligation of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte proliferation.
    Altieri DC; Stamnes SJ
    Cell Immunol; 1994 May; 155(2):372-83. PubMed ID: 8181072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase-dependent activation of human NK cell functions upon stimulation through a 58-kDa surface antigen selectively expressed on discrete subsets of NK cells and T lymphocytes.
    Melero I; Salmerón A; Balboa MA; Aramburu J; López-Botet M
    J Immunol; 1994 Feb; 152(4):1662-73. PubMed ID: 8120376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells.
    Ware CF; Crowe PD; Grayson MH; Androlewicz MJ; Browning JL
    J Immunol; 1992 Dec; 149(12):3881-8. PubMed ID: 1281193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The serine protease cofactor factor V is synthesized by lymphocytes.
    Shen NL; Fan ST; Pyati J; Graff R; LaPolla RJ; Edgington TS
    J Immunol; 1993 Apr; 150(7):2992-3001. PubMed ID: 8454869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor.
    Bolhuis RL; Roozemond RC; van de Griend RJ
    J Immunol; 1986 Jun; 136(11):3939-44. PubMed ID: 3084649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Most CD8+ cells in skin lesions of CD3+ CD4+ mycosis fungoides are CD3+ T cells that lack CD11b, CD16, CD56, CD57, and human Hanukah factor mRNA.
    Wood GS; Dubiel C; Mueller C; Abel EA; Hoppe RT; Edinger A; Weissman I; Warnke RA
    Am J Pathol; 1991 Jun; 138(6):1545-52. PubMed ID: 1828937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD3/Ti gamma A: a functional gamma-receptor complex expressed on human peripheral lymphocytes.
    Faure F; Jitsukawa S; Triebel F; Hercend T
    J Immunol; 1988 Mar; 140(5):1372-9. PubMed ID: 2964471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex.
    Anderson P; Caligiuri M; Ritz J; Schlossman SF
    Nature; 1989 Sep; 341(6238):159-62. PubMed ID: 2528695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
    van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
    J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells.
    Cron RQ; Gajewski TF; Sharrow SO; Fitch FW; Matis LA; Bluestone JA
    J Immunol; 1989 Jun; 142(11):3754-62. PubMed ID: 2523934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis of activated CD8+/CD57+ T cells is induced by some combinations of anti-CD2 mAb.
    Rouleau M; Bernard A; Lantz O; Vernant JP; Charpentier B; Senik A
    J Immunol; 1993 Oct; 151(7):3547-56. PubMed ID: 7690806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation.
    Abe R; Vandenberghe P; Craighead N; Smoot DS; Lee KP; June CH
    J Immunol; 1995 Feb; 154(3):985-97. PubMed ID: 7822814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. V7, a novel leukocyte surface protein that participates in T cell activation. I. Tissue distribution and functional studies.
    Rivas A; Ruegg CL; Zeitung J; Laus R; Warnke R; Benike C; Engleman EG
    J Immunol; 1995 May; 154(9):4423-33. PubMed ID: 7722299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo immunosuppression by targeting a novel protease receptor.
    Duchosal MA; Rothermel AL; McConahey PJ; Dixon FJ; Altieri DC
    Nature; 1996 Mar; 380(6572):352-6. PubMed ID: 8598931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
    Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
    Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific T-cell factors that initiate cellular immune responses are produced by CD4-, CD8-, V beta 8- lymphocytes and are present in nude mice.
    Vandebriel RJ; De Weger RA; Van Loveren H; Garssen J; Van Poppel MN; Van Wichen DF; Den Otter W
    Cell Immunol; 1994 Nov; 159(1):1-14. PubMed ID: 7954837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies.
    Lanier LL; Ruitenberg JJ; Allison JP; Weiss A
    J Immunol; 1986 Oct; 137(7):2286-92. PubMed ID: 2428866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential in vitro activation of CD8-CD4+ and CD4-CD8+ T lymphocytes by combinations of anti-CD2 and anti-CD3 antibodies.
    Yang SY; Rhee S; Welte K; Dupont B
    J Immunol; 1988 Apr; 140(7):2115-20. PubMed ID: 3258328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.